Vertex Pharmaceuticals
VRTX
737 hedge funds and large institutions have $45.3B invested in Vertex Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 96 funds opening new positions, 294 increasing their positions, 225 reducing their positions, and 59 closing their positions.
63% more first-time investments, than exits
New positions opened: 96 | Existing positions closed: 59
31% more repeat investments, than reductions
Existing positions increased: 294 | Existing positions reduced: 225
24% more call options, than puts
Call options by funds: $303M | Put options by funds: $244M
12% more capital invested
Capital invested by funds: $40.4B → $45.3B (+$4.85B)
4% more funds holding
Funds holding: 706 → 737 (+31)
0.82% more ownership
Funds ownership: 95.46% → 96.27% (+0.82%)
19% less funds holding in top 10
Funds holding in top 10: 16 → 13 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$730M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$191M |
| 3 |
HL
Harding Loevner
Bridgewater,
New Jersey
|
+$139M |
| 4 |
Renaissance Technologies
New York
|
+$137M |
| 5 |
State Street
Boston,
Massachusetts
|
+$119M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$367M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$151M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$138M |
| 4 |
FAM
Fred Alger Management
New York
|
-$115M |
| 5 |
Millennium Management
New York
|
-$115M |
VRTX Hedge Fund Activity: Q1 2019 in Review
737 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q1 2019, worth a combined $45.3B — up 12% from $40.4B a quarter earlier.
Buyers outnumbered sellers: 96 funds opened new VRTX positions and 59 closed out — a net gain of 37 holders — while 294 added to existing stakes and 225 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $730M. The largest seller was Ameriprise, cutting an estimated $367M.
- 737 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q1 2019, up from 706 in Q4 2018.
- Funds reported $45.3B of Vertex Pharmaceuticals stock for Q1 2019, up 12% quarter-over-quarter.
- 96 funds opened new Vertex Pharmaceuticals positions in Q1 2019 and 59 closed out, a net change of +37 holders.
- The largest Vertex Pharmaceuticals buyer in Q1 2019 was Fidelity Investments, an estimated $730M added.
- The largest Vertex Pharmaceuticals seller in Q1 2019 was Ameriprise, an estimated $367M sold.
Based on aggregated 13F filings for Q1 2019.